<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03527043</url>
  </required_header>
  <id_info>
    <org_study_id>1608017504</org_study_id>
    <nct_id>NCT03527043</nct_id>
  </id_info>
  <brief_title>Impact of Escitalopram on Sperm DNA Fragmentation</brief_title>
  <official_title>Assessing the Impact of Escitalopram on Sperm DNA Fragmentation: A Randomized Placebo Controlled</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind placebo-controlled randomized trial of daily escitalopram for 6 weeks in healthy&#xD;
      men with normal semen analyses and no psychiatric history of depression, bipolar, mania or&#xD;
      suicidal ideation. Hormone profiles, semen analysis, sperm DNA fragmentation, and sexual&#xD;
      function will be measured at baseline, after 6 weeks of therapy, and 4 weeks after&#xD;
      discontinuation of therapy (10 weeks into study).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SSRI medications, specifically escitalopram is a very commonly prescribed medication among&#xD;
      men of reproductive age. Significant evidence exists that they may be harmful for paternal&#xD;
      fertility potential in both animal and human studies. However, high quality data is lacking,&#xD;
      particularly among commonly used SSRI's such as escitalopram. As such, it is important to&#xD;
      properly evaluate the potential effect of escitalopram in a randomized placebo controlled&#xD;
      fashion. Results will be important in guiding urologists, psychiatrists and family&#xD;
      practitioners regarding discussion surrounding SSRI use in their patients interested in&#xD;
      fertility.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients converted from normal to abnormal sperm DNA fragmentation from baseline to 6 weeks</measure>
    <time_frame>0 (baseline), 6 weeks</time_frame>
    <description>TUNEL assay for sperm DNA fragmentation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in sperm DNA fragmentation</measure>
    <time_frame>0 (baseline), 6, 10 weeks</time_frame>
    <description>TUNEL assay for sperm DNA fragmentation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in sperm motility</measure>
    <time_frame>0 (baseline), 6, 10 weeks</time_frame>
    <description>Percentage of motile sperm in semen analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in progressive motility</measure>
    <time_frame>0 (baseline), 6, 10 weeks</time_frame>
    <description>Percentage of progressive motile sperm in semen analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in viability</measure>
    <time_frame>0 (baseline), 6, 10 weeks</time_frame>
    <description>Percentage of viable sperm in semen analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in concentration</measure>
    <time_frame>0 (baseline), 6, 10 weeks</time_frame>
    <description>Sperm concentration (number of sperm/mL) in semen analysis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in serum testosterone (ng/dL)</measure>
    <time_frame>0 (baseline), 6, 10 weeks</time_frame>
    <description>Serum testosterone measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum luteinizing hormone (LH) (mIU/mL)</measure>
    <time_frame>0 (baseline), 6, 10 weeks</time_frame>
    <description>Serum Luteinizing hormone measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum follicle-stimulating hormone (FSH) (mIU/mL)</measure>
    <time_frame>0 (baseline), 6, 10 weeks</time_frame>
    <description>Serum follicle-stimulating hormone measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum prolactin (ng/mL)</measure>
    <time_frame>0 (baseline), 6, 10 weeks</time_frame>
    <description>serum prolactin measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in International Index of Erectile Function Survey</measure>
    <time_frame>0 (Baseline), 6, 10 weeks</time_frame>
    <description>International Index of Erectile Function (IIEF) Survey. Severe Erectile Dysfunction (5-7), moderate (8-11), mild to moderate (12-16), mild (17-21), and no Erectile Dysfunction (22-25)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Sperm DNA Fragmentation</condition>
  <condition>Infertility, Male</condition>
  <arm_group>
    <arm_group_label>Escitalopram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg by mouth daily for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo control by mouth for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>10mg by mouth daily for 6 weeks</description>
    <arm_group_label>Escitalopram</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matched placebo control by mouth for 6 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Normal semen analyses, or semen analyses with at least 5 million sperm&#xD;
&#xD;
          -  Normal TUNEL value (&lt;7%)&#xD;
&#xD;
          -  Willing to engage in at least weekly sexual activity, with a partner or alone for the&#xD;
             duration of the 10-week study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Azoospermia or severe oligospermia (&lt;5million sperm per semen analysis)&#xD;
&#xD;
          -  Presently attempting to conceive pregnancy&#xD;
&#xD;
          -  Sexual dysfunction preventing ability to provide semen analysis throughout study or&#xD;
             engage in weekly sexual activity&#xD;
&#xD;
          -  Current psychiatric disorder including: bipolar, mania, depression, generalized&#xD;
             anxiety, social phobia, panic attacks, obsessive compulsive disorder, and&#xD;
             schizophrenia.&#xD;
&#xD;
          -  Family history of bipolar disorder, or suicide (including 2nd degree relatives)&#xD;
&#xD;
          -  Present use of psychotropic agents (prescription or herbal) or anticonvulsants&#xD;
&#xD;
          -  Use of sleeping pills&#xD;
&#xD;
          -  Alcohol consumption greater that 2oz/day&#xD;
&#xD;
          -  Use of illicit drugs&#xD;
&#xD;
          -  Inability to read, follow instructions or complete questionnaires in English.&#xD;
&#xD;
          -  Use of hormonal medications in past 3 months (androgens, androgen blockade, anabolic&#xD;
             steroids, estrogens, herbal)&#xD;
&#xD;
          -  Use of medications to enhance sexual function&#xD;
&#xD;
          -  History of chemotherapy or pelvic radiation&#xD;
&#xD;
          -  Use of Monoamine Oxidase inhibitors (MAOi's) or tricyclic antidepressants (TCAs)&#xD;
             within 14 days&#xD;
&#xD;
          -  Liver disease&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nahid Punjani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Schlegel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Phil Bach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adaobi Onunkwo</last_name>
    <phone>646-962-0534</phone>
    <email>ado2007@med.cornell.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Flynn</last_name>
      <phone>212-746-4739</phone>
      <email>thf3001@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Monica Coniglio</last_name>
      <phone>2127466676</phone>
      <email>moc4008@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nahid Punjani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Goldstein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Kashanian, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Schlegel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 19, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2018</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Male</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

